Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.

CPT: pharmacometrics & systems pharmacology - 1 Mar 2016

Tessier A, Bertrand J, Chenel M, Comets E

Abstract excerpt

We show through a simulation study how the joint analysis of data from phase I and phase II studies enhances the power of pharmacogenetic tests in pharmacokinetic (PK) studies. PK profiles were simulated under different designs along with 176 genetic markers. The null scenarios assumed no genetic effect, while under the alternative scenarios, drug clearance was associated with six genetic markers randomly sampled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Genetic Variation

Share to Metabolic Clearance Rate

Share to Nonlinear Dynamics

Share to Pharmacogenetics

Share to Sample Size

Source

Open in PubMed Open full text

Identifiers

PMID: 27069775
DOI: 10.1002/psp4.12054
PMCID: PMC4807465

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.PMID 27069775Read ↗

Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.Semantic proximity Read ↗

Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models.Semantic proximity Read ↗

Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics.Semantic proximity Read ↗

Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling.Semantic proximity Read ↗

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.Semantic proximity Read ↗

An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach.Semantic proximity Read ↗

Design of pharmacokinetic studies for latent covariates.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Statistical power considerations in genotype-based recall randomized controlled trials.Semantic proximity Read ↗

Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I StorySemantic proximity Read ↗

Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.Semantic proximity Read ↗

Haplotype-based pharmacogenetic analysis for longitudinal quantitative traits in the presence of dropout.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.